Nothing Medical about “Medical” Marijuana
- What does “medical” mean?
- “medical” marijuana cannot be prescribed by a doctor
- “medical” marijuana cannot be distributed by a pharmacist
- “medical” marijuana is not covered by insurance or Medicaid
- “medical” marijuana, a schedule 1 drug, does not have to be reported to the PDMP
- In states with medical marijuana, less than 5% of users have a serious illness like HIV, glaucoma, cancer, or MS. The average user is in his mid 30s, has a history of drug abuse, no chronic illness, and reports only pain and headaches.
- Study: Long term marijuana users seeking medical cannabis in California: demographics, social characteristics, patterns of cannabis and other drug use of 4117 applicants.
- https://www.ncbi.nlm.nih.gov/pubmed/17980043
- The National Academy of Medicine convened a panel of sixteen leading medical experts to analyze the scientific literature on cannabis. The report they prepared, which came out in January of 2017, is over 400 pages. Some things they looked at:
- Smoking pot is widely believed to diminish nausea associated with chemotherapy. The panel pointed out, “there are no good-quality randomized trials investigating this option.”
- In the US we are using marijuana as a treatment for pain, but “very little is known about the efficacy, dose, routes of administration, or side effects of commonly used and commercially available cannabis products in the United States.”
- Is it good for epilepsy? “Insufficient evidence.”
- Tourette’s syndrome? “Limited evidence. “
- A.L.S., Huntington’s, and Parkinson’s? “Insufficient evidence.”
- Irritable-bowel syndrome? “Insufficient evidence.”
- Dementia and glaucoma? “Probably not. “
- Depression? “Probably not.”
- As the National Academy panel declared, in one of its few unequivocal conclusions, “Cannabis use is likely to increase the risk of developing schizophrenia and other psychoses; the higher the use, the greater the risk.”
- From the New Yorker story on the study:
- We need proper studies, the panel concluded, on the health effects of cannabis on children and teen-agers and pregnant women and breast-feeding mothers and “older populations” and “heavy cannabis users.”
- The panel also called for investigation into “the pharmacokinetic and pharmacodynamic properties of cannabis, modes of delivery, different concentrations, in various populations, including the dose-response relationships of cannabis and THC or other cannabinoids.”
- Figuring out the “dose-response relationship” of a new compound is something a pharmaceutical company does from the start of trials in human subjects, as it prepares a new drug application for the F.D.A.
- Too little of a powerful drug means that it won’t work. Too much means that it might do more harm than good. The amount of active ingredient in a pill and the metabolic path that the ingredient takes after it enters your body—these are things that drugmakers will have painstakingly mapped out before the product comes on the market, with a tractor-trailer full of supporting documentation
- By NOT requiring the marijuana industry, which is heavily propped up by investments from the tobacco industry, we are allowing big business to forgo the FDA process that protects patients and ensures quality control.
- The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine.
- The FDA requires carefully conducted studies (clinical trials) in hundreds to thousands of human subjects to determine the benefits and risks of a possible medication. So far, researchers haven’t conducted enough large-scale clinical trials that show that the benefits of the marijuana plant outweigh its risks in patients it’s meant to treat.
- The process to bring a new drug to market is a rigorous one and one that is costly to the pharmaceutical companies that seek to sell it. It usually takes about 12 years and costs between at least one billion dollars, and often more than two billion.
- Marijuana is a $10 Billion dollar industry in the Untied States.
- Cronos, which became the first marijuana stock to go from the over-the-counter exchange to a major U.S. exchange, made waves in early December when it announced that tobacco giant Altria (NYSE:MO) would be taking a $1.8 billion equity stake in the company. Altria now has a 45% stake in Cronos Group, with the ability to exercise warrants it also received to boost its stake up to 55%. Should those warrants be exercised, Cronos would receive an additional $1.05 billion from Altria.